-
1.发明申请ANALYSIS AND USE OF PAR1 POLYMORPHISMS FOR EVALUATING THE RISK OF CARDIOVASCULAR DISEASE 失效分析和使用PAR1多态性评估心血管疾病风险公开(公告)号：US20100221714A1
公开(公告)日：2010-09-02
申请号：US12567942
申请日：2009-09-28
申请人： Detlef KOZIAN , Joerg CZECH , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Joerg CZECH , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
CPC分类号： C12Q1/6883 , C07H17/08 , C07K14/723 , C12Q2600/156
摘要： The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis.
摘要翻译： 本发明涉及包含位点3090和/或3329上的PAR1基因的遗传变异的多核苷酸序列。人类中这些变体的发生与特定心血管疾病的增加的发生相关。 本发明还涉及用于检测用于患者诊断目的的所述遗传变异的方法。
-
2.发明申请METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM 失效通过确定TAF1-ILE47多态性来识别致病性疾病的风险的方法公开(公告)号：US20090239237A1
公开(公告)日：2009-09-24
申请号：US12474794
申请日：2009-05-29
申请人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： C12Q1/68
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
3.发明申请ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF 审中-公开EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺动脉栓塞的联合及其使用公开(公告)号：US20120208200A1
公开(公告)日：2012-08-16
申请号：US13457781
申请日：2012-04-27
申请人： Detlef KOZIAN , Evi KOSTENIS , Karl-Ernst SIEGLER , Martina JACOBS , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Evi KOSTENIS , Karl-Ernst SIEGLER , Martina JACOBS , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： C12Q1/68 , G01N33/566
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
4.发明申请METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM 失效通过确定TAF1-lle347多态性鉴定致病性疾病风险的方法公开(公告)号：US20110223628A1
公开(公告)日：2011-09-15
申请号：US13109111
申请日：2011-05-17
申请人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Stefan SCHAEFER , Bernward SCHOELKENS , Karl-Ernst SIEGLER , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： C12Q1/37
CPC分类号： G01N33/6893 , Y10S436/811
摘要： The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.
摘要翻译： 本发明涉及一种鉴定血栓形成疾病风险的方法，包括但不限于心房颤动，中风，延迟性间歇性神经功能缺损（PRIND），短暂性缺血发作（TIA），动脉粥样硬化性脑血管病（CVD）和/或冠状动脉疾病 心脏病以及用于选择具有血栓形成障碍风险的患者的方法，用于鉴定用于治疗或预防血栓形成疾病的药物的方法以及用于制备药物的方法和诊断方法 采用TAFI-Ile347多态性。
-
5.发明申请METHOD OF DIAGNOSIS OF A PREDISPOSITION TO DEVELOP THROMBOTIC DISEASE AND ITS USES 审中-公开诊断发展为血栓病的预防方法及其应用公开(公告)号：US20100221738A1
公开(公告)日：2010-09-02
申请号：US12781027
申请日：2010-05-17
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P2X1 promoter variant and its use for screening for an anti-thrombotic agent, and to methods for identifying an individual that can be prophylactically or therapeutically treated with an anti-thrombotic agent, or for adapting a therapeutic or prophylactic dose of an anti-thrombotic agent.
摘要翻译： 本发明涉及诊断P2V1启动子变体及其用于筛选抗血栓形成剂的用于发展血栓形成疾病，测试系统及其用于诊断倾向于发展血栓形成疾病的用途的倾向性的方法 以及用于鉴定可以用抗血栓形成剂预防性或治疗性治疗的个体的方法，或用于调整治疗或预防剂量的抗血栓形成剂。
-
6.发明申请ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF 失效EDG5多态性V286A与II型糖尿病和静脉血栓形成/肺动脉栓塞的联合及其使用公开(公告)号：US20070298509A1
公开(公告)日：2007-12-27
申请号：US11834998
申请日：2007-08-07
申请人： Detlef KOZIAN , Evi KOSTENIS , Karl-Ernst STEGLER , Martina JACOBS , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
发明人： Detlef KOZIAN , Evi KOSTENIS , Karl-Ernst STEGLER , Martina JACOBS , Jean-Francois DELEUZE , Sylvain RICARD , Sandrine MACE
IPC分类号： G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.
摘要翻译： 本发明涉及鉴定受试者中II型糖尿病，静脉血栓形成或肺栓塞风险增加的方法，其中286位从缬氨酸（Val）到丙氨酸（Ala）的氨基酸交换的存在 在取自受试者的生物样品中的EDG5蛋白中。
-
公开(公告)号：US20120065078A1
公开(公告)日：2012-03-15
申请号：US13298590
申请日：2011-11-17
IPC分类号： C12Q1/68 , G01N33/573 , C12Q1/48 , C40B20/00
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/573 , G01N2333/91215 , G01N2800/32 , G01N2800/52
摘要： The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease.
摘要翻译： 本发明涉及体外或体内诊断心血管疾病，特别是高血压，狭窄，血管闭塞和/或其他血栓事件的方法，其中编码人的核酸的位置950处的核苷酸 确定ARK2蛋白或人的样品的人ARK2蛋白的298位的氨基酸以及使用ARK2来开发和/或制备治疗心血管疾病的药物。
-
8.发明申请EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES 失效EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用公开(公告)号：US20110123515A1
公开(公告)日：2011-05-26
申请号：US13015994
申请日：2011-01-28
申请人： Detlef KOZIAN , Matthias HERRMANN
发明人： Detlef KOZIAN , Matthias HERRMANN
CPC分类号： C12N9/0071
摘要： The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
摘要翻译： 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病，特别是中风，长期可逆性缺血性神经功能缺损（PRIND）， 经皮缺血发作（TIA），心肌梗死和/或早期心肌梗死。
-
9.发明申请EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASES 失效EGLN2变异体及其在预防或治疗血栓性疾病和冠状动脉疾病中的应用公开(公告)号：US20120096571A1
公开(公告)日：2012-04-19
申请号：US13331581
申请日：2011-12-20
申请人： Detlef KOZIAN , Matthias HERRMANN
发明人： Detlef KOZIAN , Matthias HERRMANN
CPC分类号： C12N9/0071
摘要： The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
摘要翻译： 本发明涉及具有丝氨酸或亮氨酸的氨基酸序列58位的人EGLN2变异体及其在预防或治疗血栓栓塞或冠心病，特别是中风，长期可逆性缺血性神经功能缺损（PRIND）， 经皮缺血发作（TIA），心肌梗死和/或早期心肌梗死。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.024 秒)
